Literature DB >> 26380651

Markers of bacterial translocation in end-stage liver disease.

Ioannis Koutsounas1, Garyfallia Kaltsa1, Spyros I Siakavellas1, Giorgos Bamias1.   

Abstract

Bacterial translocation (BT) refers to the passage of viable bacteria or bacterial products from the intestinal lumen, through the intestinal epithelium, into the systemic circulation and extraintestinal locations. The three principal mechanisms that are thought to be involved in BT include bacterial overgrowth, disruption of the gut mucosal barrier and an impaired host defence. BT is commonly observed in liver cirrhosis and has been shown to play an important role in the pathogenesis of the complications of end stage liver disease, including infections as well as hepatic encephalopathy and hepatorenal syndrome. Due to the importance of BT in the natural history of cirrhosis, there is intense interest for the discovery of biomarkers of BT. To date, several such candidates have been proposed, which include bacterial DNA, soluble CD14, lipopolysaccharides endotoxin, lipopolysaccharide-binding protein, calprotectin and procalcitonin. Studies on the association of these markers with BT have demonstrated not only promising data but, oftentimes, contradictory results. As a consequence, currently, there is no optimal marker that may be used in clinical practice as a surrogate for the presence of BT.

Entities:  

Keywords:  Bacterial DNA; Bacterial translocation; Biomarkers; Calprotectin; Cirrhosis; End stage liver disease; Lipopolysaccharide-binding protein; Lipopolysaccharides endotoxin; Procalcitonin; Soluble CD14

Year:  2015        PMID: 26380651      PMCID: PMC4568487          DOI: 10.4254/wjh.v7.i20.2264

Source DB:  PubMed          Journal:  World J Hepatol


  99 in total

1.  Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis.

Authors:  Pablo Bellot; Juan Carlos García-Pagán; Rubén Francés; Juan G Abraldes; Miguel Navasa; Miguel Pérez-Mateo; José Such; Jaime Bosch
Journal:  Hepatology       Date:  2010-10-26       Impact factor: 17.425

2.  Is detection of bacterial DNA in ascitic fluid of clinical relevance?

Authors:  Beate Appenrodt; Lutz E Lehmann; Lydia Thyssen; Martin Gentemann; Christian Rabe; Ernst Molitor; Jonel Trebicka; Frank Stüber; Tilman Sauerbruch
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-12       Impact factor: 2.566

3.  LPS-induced imbalanced expression of hepatic vascular stress genes in cirrhosis: possible mechanism of increased susceptibility to endotoxemia.

Authors:  Rajiv Baveja; Steve Keller; Yukihiro Yokoyama; Natalie Sonin; Mark G Clemens; Jian X Zhang
Journal:  Shock       Date:  2002-04       Impact factor: 3.454

4.  Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis.

Authors:  Vasiliki Arvaniti; Gennaro D'Amico; Giuseppe Fede; Pinelopi Manousou; Emmanuel Tsochatzis; Maria Pleguezuelo; Andrew Kenneth Burroughs
Journal:  Gastroenterology       Date:  2010-06-14       Impact factor: 22.682

5.  Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells.

Authors:  Yong-Han Paik; Robert F Schwabe; Ramón Bataller; Maria P Russo; Christian Jobin; David A Brenner
Journal:  Hepatology       Date:  2003-05       Impact factor: 17.425

6.  Serum and ascitic procalcitonin levels in cirrhotic patients with spontaneous bacterial peritonitis: diagnostic value and relationship to pro-inflammatory cytokines.

Authors:  A Viallon; F Zeni; V Pouzet; C Lambert; S Quenet; G Aubert; S Guyomarch; B Tardy; J C Bertrand
Journal:  Intensive Care Med       Date:  2000-08       Impact factor: 17.440

7.  Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites.

Authors:  Agustín Albillos; Antonio de-la-Hera; Melchor Alvarez-Mon
Journal:  Lancet       Date:  2004-05-15       Impact factor: 79.321

Review 8.  Initial responses to endotoxins and Gram-negative bacteria.

Authors:  Didier Heumann; Thierry Roger
Journal:  Clin Chim Acta       Date:  2002-09       Impact factor: 3.786

9.  Intestinal permeability is increased in patients with advanced cirrhosis.

Authors:  Sonia Pascual; José Such; Angel Esteban; Pedro Zapater; Juan A Casellas; José R Aparicio; Eva Girona; Ana Gutiérrez; Fernando Carnices; Jose M Palazón; Javier Sola-Vera; Miguel Pérez-Mateo
Journal:  Hepatogastroenterology       Date:  2003 Sep-Oct

10.  Human monocyte CD14 is upregulated by lipopolysaccharide.

Authors:  R Landmann; H P Knopf; S Link; S Sansano; R Schumann; W Zimmerli
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

View more
  14 in total

1.  Is small intestinal bacterial overgrowth a cause of hyperdynamic circulation in cirrhosis?

Authors:  Roman Maslennikov; Chavdar Pavlov; Vladimir Ivashkin
Journal:  Turk J Gastroenterol       Date:  2019-11       Impact factor: 1.852

2.  The proportion of different interleukin-17-producing T-cell subsets is associated with liver fibrosis in chronic hepatitis C.

Authors:  Fabio C O F Cachem; Aleida S Dias; Clarice Monteiro; José Roberto Castro; Gabriel Fernandes; Letícia Delphim; Adilson J Almeida; Felipe Tavares; Alessandra M A Maciel; Marcia M Amendola-Pires; Carlos E Brandão-Mello; Cleonice A M Bento
Journal:  Immunology       Date:  2017-03-13       Impact factor: 7.397

3.  Neurocognitive impairment is worse in HIV/HCV-coinfected individuals with liver dysfunction.

Authors:  Jyoti Barokar; Allen McCutchan; Reena Deutsch; Bin Tang; Mariana Cherner; Ajay R Bharti
Journal:  J Neurovirol       Date:  2019-07-07       Impact factor: 2.643

4.  Expression of α-Defensins, CD20+ B-lymphocytes, and Intraepithelial CD3+ T-lymphocytes in the Intestinal Mucosa of Patients with Liver Cirrhosis: Emerging Mediators of Intestinal Barrier Function.

Authors:  Georgios I Tsiaoussis; Eleni C Papaioannou; Eleni P Kourea; Stelios F Assimakopoulos; Georgios I Theocharis; Michalis Petropoulos; Vasileios I Theopistos; Georgia G Diamantopoulou; Zoi Lygerou; Iris Spiliopoulou; Konstantinos C Thomopoulos
Journal:  Dig Dis Sci       Date:  2018-06-07       Impact factor: 3.199

Review 5.  Gut microbiome as a clinical tool in gastrointestinal disease management: are we there yet?

Authors:  Eamonn M M Quigley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-03-30       Impact factor: 46.802

6.  Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study.

Authors:  Yoo Li Lim; Moon Young Kim; Yoon Ok Jang; Soon Koo Baik; Sang Ok Kwon
Journal:  Gut Liver       Date:  2017-09-15       Impact factor: 4.519

7.  Influence of Dietary Patterns on Plasma Soluble CD14, a Surrogate Marker of Gut Barrier Dysfunction.

Authors:  Fred K Tabung; Brenda M Birmann; Mara M Epstein; Otoniel Martínez-Maza; Elizabeth C Breen; Kana Wu; Edward L Giovannucci
Journal:  Curr Dev Nutr       Date:  2017-10-17

8.  Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites.

Authors:  Matthew J Stotts; Amanda Cheung; Muhammad B Hammami; David J Westrich; Eric Anderson; Lauren Counts; Alex S Befeler; Adrian M Di Bisceglie; Charlene Prather
Journal:  Cureus       Date:  2021-06-02

9.  Alteration of the serum microbiome composition in cirrhotic patients with ascites.

Authors:  Alba Santiago; Marta Pozuelo; Maria Poca; Cristina Gely; Juan Camilo Nieto; Xavier Torras; Eva Román; David Campos; Guillaume Sarrabayrouse; Silvia Vidal; Edilmar Alvarado-Tapias; Francisco Guarner; German Soriano; Chaysavanh Manichanh; Carlos Guarner
Journal:  Sci Rep       Date:  2016-04-26       Impact factor: 4.379

10.  Probiotic Mixture Golden Bifido Prevents Neonatal Escherichia coli K1 Translocation via Enhancing Intestinal Defense.

Authors:  Qing Zeng; Xiaolong He; Santhosh Puthiyakunnon; Hansen Xiao; Zelong Gong; Swapna Boddu; Lecheng Chen; Huiwen Tian; Sheng-He Huang; Hong Cao
Journal:  Front Microbiol       Date:  2017-09-20       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.